Dupilumab-associated ocular surface disease is characterized by a shift from Th2/Th17 toward Th1/Th17 inflammation,Allergy

当前位置： X-MOL 学术 › Allergy › 论文详情

Our official English website, www.x-mol.net, welcomes your feedback! (Note: you will need to create a separate account there.)

Dupilumab-associated ocular surface disease is characterized by a shift from Th2/Th17 toward Th1/Th17 inflammation
Allergy ( IF 12.6 ) Pub Date : 2024-02-05 , DOI: 10.1111/all.16045
Kathrin Thormann ₁ , Anne-Sophie Lüthi ₁ , Felix Deniau ₂ , Anja Heider ₃ , Simone Cazzaniga _{1,

4} , Susanne Radonjic-Hoesli ₁ , Mathias Lehmann ₁ , Christoph Schlapbach ₁ , Elio L Herzog _{2,

5,

6} , Marco Kreuzer ₇ , Martin S Zinkernagel _{2,

5} , Cezmi A Akdis ₃ , Denise C Zysset-Burri _{2,

5} , Hans-Uwe Simon _{8,

9} , Dagmar Simon ₁

Affiliation

Dupilumab is used for the treatment of atopic dermatitis (AD). Approximately one third of AD patients develop a dupilumab-associated ocular surface disease (DAOSD), of which the pathomechanism is poorly understood. This study aimed at investigating inflammatory markers in tear fluids of patients on dupilumab therapy.

中文翻译：

Dupilumab 相关眼表疾病的特点是从 Th2/Th17 炎症向 Th1/Th17 炎症的转变

Dupilumab 用于治疗特应性皮炎 (AD)。大约三分之一的 AD 患者会出现 dupilumab 相关眼表疾病 (DAOSD)，但其病理机制尚不清楚。本研究旨在调查接受 dupilumab 治疗的患者泪液中的炎症标志物。

更新日期：2024-02-05

点击分享查看原文

点击收藏

公开下载

阅读更多本刊新发论文本刊介绍/投稿指南